"Peptidyl-Dipeptidase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992)
| Descriptor ID |
D007703
|
| MeSH Number(s) |
D08.811.277.656.350.350.687
|
| Concept/Terms |
Peptidyl-Dipeptidase A- Peptidyl-Dipeptidase A
- Peptidyl Dipeptidase A
- Angiotensin I-Converting Enzyme
- Angiotensin I Converting Enzyme
- Carboxycathepsin
- CD143 Antigens
- Kininase II
- Dipeptidyl Peptidase A
- Antigens, CD143
- Angiotensin Converting Enzyme
- Kininase A
|
Below are MeSH descriptors whose meaning is more general than "Peptidyl-Dipeptidase A".
Below are MeSH descriptors whose meaning is more specific than "Peptidyl-Dipeptidase A".
This graph shows the total number of publications written about "Peptidyl-Dipeptidase A" by people in this website by year, and whether "Peptidyl-Dipeptidase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2020 | 7 | 5 | 12 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Peptidyl-Dipeptidase A" by people in Profiles.
-
Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2-Infected Young Individuals: Is It Type 1 Diabetes? Diabetes. 2022 12 01; 71(12):2656-2663.
-
Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention. PLoS One. 2022; 17(7):e0271303.
-
Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2. J Mol Endocrinol. 2022 06 17; 69(2):R63-R79.
-
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nat Biotechnol. 2022 08; 40(8):1270-1275.
-
Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Med. 2022 02; 19(2):e1003897.
-
"Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry. Int J Mol Sci. 2021 Aug 20; 22(16).
-
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. Hypertension. 2020 11; 76(5):1350-1367.
-
Cigarette Smoking and COVID-19: A Complex Interaction. Am J Respir Crit Care Med. 2020 08 01; 202(3):471-472.
-
Tobacco, but Not Nicotine and Flavor-Less Electronic Cigarettes, Induces ACE2 and Immune Dysregulation. Int J Mol Sci. 2020 Jul 31; 21(15).
-
Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.